Intrapulmonary percussion ventilation added to breathing support for adults with pneumonia on a ventilator

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with pneumonia who are invasively mechanically ventilated and have an oxygenation index (PaO2/FiO2) ≤ 300 and are expected to require ventilation ≥ 48 hours will receive either standard airway clearance alone or standard care plus intrapulmonary percussive ventilation (IPV). The protocol includes serial electrical impedance tomography (EIT) monitoring at predefined time points to track regional and global lung ventilation and routine clinical and ventilator parameter assessments. Key outcomes include duration of invasive mechanical ventilation, changes in oxygenation and lung mechanics, pulmonary infection scores, and safety signals. Safety monitoring will pay particular attention to hemodynamic stability and intracranial pressure during IPV.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years;
2. Meeting the diagnostic criteria for pulmonary infection, defined as follows: meeting the diagnostic criteria for hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP) according to the Chinese Guidelines for the Diagnosis and Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia in Adults (2018 edition), or meeting the diagnostic criteria for community-acquired pneumonia (CAP) according to the Chinese Guidelines for the Diagnosis and Treatment of Community-Acquired Pneumonia in Adults (2016 edition);
3. Oxygenation index (PaO₂/FiO₂) ≤ 300;
4. Currently receiving invasive mechanical ventilation, with no planned liberation from invasive mechanical ventilation within the next 24 hours;
5. Receiving analgesia and sedation;
6. Written informed consent provided by the patient's family member or legally authorized representative.

Exclusion Criteria:

1. Presence of severe hemodynamic instability (norepinephrine dose \> 0.5 μg/kg/min);
2. Markedly elevated intracranial pressure (\> 25 mmHg) or a condition requiring strict intracranial pressure control;
3. Severe pulmonary bullae, untreated tension pneumothorax or undrained mediastinal emphysema;
4. Unstable chest wall, flail chest, recent thoracic or airway surgery, or severe thoracic spine injury;
5. Active massive hemoptysis;
6. Severe bronchospasm or inability to tolerate fluctuations in airway pressure;
7. Inability to place the EIT chest belt, such as open thoracic surgical wounds or skin lesions at the belt placement site;
8. Receiving extracorporeal membrane oxygenation (ECMO);
9. Acute exacerbation of chronic obstructive pulmonary disease as the primary reason for the current episode of invasive mechanical ventilation;
10. Expected death within 24 hours, or a decision already made to withhold or withdraw life-sustaining treatment;
11. Pregnancy or breastfeeding;
12. Concurrent participation in another clinical trial.

Where it's running

• Zhongnan Hospital of Wuhan University
  Wuhan, Hubei, China Recruiting

Study contacts

• Study coordinator: Qingting Xie
• Email: qingtingxxx@163.com
• Phone: +86 13296652698

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Respiratory Physiotherapy in Critically Ill Pneumonia Patients

  This study tests whether a structured breathing and chest therapy program can change inflammatory biomarkers in adults with pneumonia in the ICU compared to usual care.

  Recruiting Hospital H+ Queretaro · Querétaro · NCT07909616

• AI-powered CT help to guide pneumonia care

  A multicenter trial tests whether using a chest CT–based AI report to guide care reduces death or need for new organ support in adults with pneumonia.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07895290

• Wintergreen oil inhalation for shortness of breath in pneumonia patients

  Hospitals will test whether inhaling wintergreen essential oil helps relieve dyspnea in adults with pneumonia.

  Recruiting Far Eastern Memorial Hospital · New Taipei City, Taipei · NCT07894835

• Optimising Antibiotic Use for Paediatric LRTIs in Africa

  This study tests whether using point-of-care CRP tests together with the PREPARE score can safely reduce antibiotic use in infants aged 2–24 months with lower respiratory infections in a Johannesburg hospital.

  Recruiting University of Witwatersrand, South Africa · Johannesburg, Gauteng · NCT07841691

• Buteyko Breathing vs Incentive Spirometry for Smog-Induced Pneumonia

  We’re testing whether the Buteyko Breathing Technique can improve oxygen levels and breathe easier for adults with smog-related pneumonia compared to incentive spirometry.

  Recruiting Lahore University of Biological and Applied Sciences · Lahore, Punjab Province · NCT07759583

• FUNGAL-P: A score to spot fungal pneumonia early in adults with pneumonia

  Aimed at adults with pneumonia, this study tests a new score to help identify fungal pneumonia sooner so doctors can test appropriately and start antifungal treatment when needed.

  Recruiting Azienda Ospedaliero-Universitaria Careggi · Florence · NCT07681583

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.